Analyst Price Target is $6.00
▲ +248.84% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Dyadic International in the last 3 months. The average price target is $6.00, with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 248.84% upside from the last price of $1.72.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in Dyadic International.
Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It focuses on further improving and applying its proprietary C1 technology, which is used in the discovery, development, and manufacture of biologic medicines and vaccines. The company was founded by Mark A. Emalfarb in 1979 and is headquartered in Jupiter, FL.